{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:30:02Z","timestamp":1793626202326,"version":"4.5.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Shanghai Municipality Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"National Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013104","name":"Shanghai Medicine and Health Development Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai Municipality Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.apjo.2026.100383","type":"journal-article","created":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:58:34Z","timestamp":1792825114000},"page":"100383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of 0.01%, 0.02% and 0.04% atropine eyedrops vs placebo on myopia incidence in pre-myopic children: A randomized clinical trial"],"prefix":"10.1016","author":[{"given":"Jingjing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhuang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanxi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-7040","authenticated-orcid":false,"given":"Jinliuxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.apjo.2026.100383_bib1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.apjo.2026.100383_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","article-title":"Myopia","volume":"6","author":"Baird","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.apjo.2026.100383_bib3","unstructured":"Commission N.H. Transcript of a press conference held by the National Health Commission on July 13, 2021[EB\/OL].(2021-07-13)."},{"issue":"7","key":"10.1016\/j.apjo.2026.100383_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/bjophthalmol-2017-311266","article-title":"Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling","volume":"102","author":"Fricke","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100383_bib5","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.18-25957","article-title":"IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies","volume":"60","author":"Flitcroft","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.apjo.2026.100383_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/iovs.62.5.7","article-title":"IMI 2021 Yearly Digest","volume":"62","author":"Jong","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.apjo.2026.100383_bib7","first-page":"1314","article-title":"Epidemiology of premyopia among children aged 6-8 in Shanghai","volume":"43","author":"Ziyi","year":"2022","journal-title":"Chin J Sch Health"},{"issue":"8","key":"10.1016\/j.apjo.2026.100383_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/ceo.13195","article-title":"Cohort study with 4-year follow-up of myopia and refractive parameters in primary schoolchildren in Baoshan District, Shanghai","volume":"46","author":"Ma","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100383_bib9","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1167\/iovs.18-26247","article-title":"Axial growth and lens power loss at myopia onset in singaporean children","volume":"60","author":"Rozema","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.apjo.2026.100383_bib10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"issue":"32","key":"10.1016\/j.apjo.2026.100383_bib11","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.2174\/1381612821666150909095403","article-title":"The role of atropine eye drops in myopia control","volume":"21","author":"Grzybowski","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.apjo.2026.100383_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.apjo.2026.100383_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"Clark","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.apjo.2026.100383_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100383_bib15","unstructured":"Optometry Group of Ophthalmology Branch of Chinese Medical Association, Ophthalmology and Optometry Committee of Ophthalmologists Association of Chinese Doctor Association. Expert Consensus on Application of Low-Concentration Atropine Eye Drops in the Prevention and Control of Myopia in Children and Adolescents (2024). Chinese Journal of Optometry Ophthalmology and Visual Science. 2024;26(9):641-648. doi:10.3760\/cma.j.cn."},{"issue":"6","key":"10.1016\/j.apjo.2026.100383_bib16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.2022.24162","article-title":"Effect of low-concentration atropine eyedrops vs placebo on myopia incidence in children: the LAMP2 randomized clinical trial","volume":"329","author":"Yam","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.apjo.2026.100383_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/ijo.IJO_1462_21","article-title":"Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes","volume":"70","author":"Jethani","year":"2022","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100383_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/jop.2009.0135","article-title":"Prevention of myopia onset with 0.025% atropine in premyopic children","volume":"26","author":"Fang","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.apjo.2026.100383_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/ceo.13065","article-title":"Design and methodology of the Shanghai child and adolescent large-scale eye study (SCALE)","volume":"46","author":"He","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100383_bib20","unstructured":"National Health Commission of the People\u2019s Republic of China. Guidelines on Appropriate Technologies for Myopia Prevention and Control in Children and Adolescents (Updated Version). 2021 [cited 2026-06-03]. Available from: https:\/\/www.nhc.gov.cn\/jkj\/c100062\/202110\/a05ccaf5773a436486d2d79b59c0a5e9.shtml."},{"key":"10.1016\/j.apjo.2026.100383_bib21","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00431-023-04921-5","article-title":"Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children\u2014a prospective, randomized, double-masked, and crossover trial","volume":"182","author":"Wang","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.apjo.2026.100383_bib22","article-title":"Safety and efficacy of atropine 0.05% Versus 0.01% for prevention of myopic progression in indian children: a randomized clinical trial","volume":"17","author":"Janti","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.apjo.2026.100383_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-026-04845-2","article-title":"Efficacy of 0.01% low-dose atropine therapy for the myopia and premyopia in children: a meta-analysis and systematic review","author":"Huang","year":"2026","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100383_bib24","article-title":"STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24-Month Results of a Randomized, Double-Masked, Vehicle-Controlled Trial of Atropine Sulfate 0.01% and 0.03","author":"Korenfeld","year":"2026","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.apjo.2026.100383_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/ovs2.70007","article-title":"Control of myopia progression by low-dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments\/highly aspherical lenslets spectacles, and combined therapy in European children: a 3-year retrospective study","volume":"103","author":"Gr\u00e9goire","year":"2026","journal-title":"Optom Vis Sci"},{"issue":"8","key":"10.1016\/j.apjo.2026.100383_bib26","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ophtha.2020.12.036","article-title":"Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: low-concentration atropine for myopia progression study","volume":"128","author":"Li","year":"2021","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.apjo.2026.100383_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/08164622.2023.2202306","article-title":"Predicting the child who will become myopic \u2013 can we prevent onset?","volume":"106","author":"Wang","year":"2023","journal-title":"Clin Exp Optom"},{"issue":"7","key":"10.1016\/j.apjo.2026.100383_bib28","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/opo.70018","article-title":"0.01% Atropine for myopia prevention in pre-myopia (AMPP study)","volume":"45","author":"He","year":"2025","journal-title":"Ophthalmic Physiol Opt"},{"issue":"1","key":"10.1016\/j.apjo.2026.100383_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216209892600109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216209892600109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:56:26Z","timestamp":1793624186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216209892600109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"alternative-id":["S216209892600109X"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100383","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of 0.01%, 0.02% and 0.04% atropine eyedrops vs placebo on myopia incidence in pre-myopic children: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100383"}}